Biotechnology

Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies

JERSEY CITY, N.J. and SHANGHAI, Dec. 2, 2022 /PRNewswire/ -- Focus-X Therapeutics (referred to here as "Focus-X"), a nuclide drug company that was invested in and incubated by Viva Biotech, successfully reached an acquisition agreement with Full-Life Technologies Co., Ltd. (referred to here as "...

2022-12-02 18:23 4647

CUVET Successfully Developed the First Stem Cell Transplantation Technology to Treat Pet Diabetes

BANGKOK, Dec. 2, 2022 /PRNewswire/ -- For the first time in Thailand, a research team from Chula's Faculty of Veterinary Science (CUVET) is the first to have successfully developed a method to culture dog pancreatic cells from stem cells and cell transplantation technology. They aim to test the m...

2022-12-02 10:00 3303

Innoforce Opens GMP Manufacturing Facility & Corporate Headquarters in Hangzhou, China to Provide CDMO Services for Global Supply of RNA, Cell & Gene Therapies

The new site adds to its capacity in China & US to provide end-to-end process development and global manufacturing services for advanced therapies HANGZHOU, China, Dec. 2, 2022 /PRNewswire/ -- Innoforce, a global provider of end-to-end contract development and manufacturing services (CDMO), today...

2022-12-02 06:00 3663

BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine

VANCOUVER, BC, Dec. 1, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce the successful sterile and bacteria-free test-run production of BVX-0918, the Company's bi-haptenized autologous ovarian cancer vaccine.   ...

2022-12-01 21:00 5471

MGI Cements Its Presence and Contribution in Singapore's Genomics Landscape at ESMO Asia Congress 2022

SINGAPORE, Dec. 1, 2022 /PRNewswire/ -- MGI Tech Co. Ltd. (MGI), a company committed to building core tools and technology to lead life science, will join global and Asian cancer professionals at the ESMO Asia Congress 2022 taking place 2-4 December inSingapore. In addition, MGI will introduce...

2022-12-01 17:10 3105

NCH ASIA PACIFIC PUTS BACK THE FUN IN CSR ACTIVITIES WITH NCH PLOGGO

* NCH PLOGGO is a "pick up litter while you go" fun run with cleaning * PLOGGO was launched last Sept 2022 and is run all over NCH ASIA PACIFIC countries SINGAPORE, Dec. 1, 2022 /PRNewswire/ -- NCH ASIA PACIFIC renews its commitment to health and community service with the launch of NCH PLOGGO...

2022-12-01 09:00 2594

Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index

LONDON and HONG KONG, Nov. 30, 2022 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced that its board of directors has authorized a share repurchase program, and that it has been included as a c...

2022-11-30 22:15 4100

First Patient dosed in a Head-to-Head First-Line Bridging Study of HANSIZHUANG for ES-SCLC treatment in the US

SHANGHAI, Nov. 30, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient was dosed in NCT05468489, a bridging head-to-head trial inthe United States comparing HANSIZHUANG (serplulimab), an innovative anti-PD-1 monoclonal antibody (mAb) independently develo...

2022-11-30 08:00 4176

TargEDys and SymbioPharm enter an exclusive partnership to launch SymbioLife® Satylia® in Germany

PARIS, Nov. 29, 2022 /PRNewswire/ -- TargEDys and SymbioPharm signed an exclusive marketing and distribution agreement for the launch of SymbioLife® Satylia® inGermany. The novel dietary supplement based on the next-generation probioticHafnia alvei HA4597 will be available from January 2023. Sym...

2022-11-29 18:15 3530

Probiotic strain SNZ 1969® helps manage IBS-D & IBS-C symptoms effectively, latest clinical study shows

HYDERABAD, India, Nov. 29, 2022 /PRNewswire/ -- Latest study shows Sanzyme Biologics'sBacillus coagulans SNZ 1969® (Weizmannia coagulans SNZ 1969), a natural spore forming probiotic strain over five decades of use and more than 30 human studies across age groups found to be effective in managing ...

2022-11-29 15:44 4123

BGI Genomics, Naleya Genomics Indonesia, MGI, and Bumame contribute aid packages to Cianjur earthquake relief efforts

CIANJUR, Indonesia, Nov. 29, 2022 /PRNewswire/ -- A 5.6-magnitude earthquake struck the Cianjur district,West Java last Monday (Nov. 21, 2022). As part of earthquake relief efforts, BGI Genomics, its subsidiary Naleya Genomics Indonesia (NGI) and MGI are partnering withIndonesia's leading healthc...

2022-11-29 08:38 3988

TELEHEALTH USAGE IN ASIA PACIFIC FOR PEOPLE LIVING WITH HIV INCREASING, BUT DATA PRIVACY AND LACK OF PERSONAL CONTACT STILL SEEN AS A BARRIER TO WIDER USE

- Half of the people living with HIV (PLHIV) and individuals at-risk (IARs) surveyed in the region increased their usage of telehealth services over the past year; this is driven by the availability of new telehealth services during pandemic - Top factor impacting usage of telehealth services fo...

2022-11-28 15:00 3511

Nuance Pharma announces partnership with DKSH to launch Bentrio™ Nasal Spray in Hong Kong and Macau

SHANGHAI, Nov. 28, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces partnership with DKSH Hong Kong (DKSH HK) Business Unit Healthcare to launch BentrioTM nasal spray in Hong Kong and Macau, marking the very first milestone of Nuance Pharma's commercial expansion in the APAC market. U...

2022-11-28 13:40 7794

Innovent Announced Clinical Data of Multiple Trials Will be Presented at the 2022 ESMO-IO and ASH Annual Meetings

ROCKVILLE, Md. and SUZHOU, China, Nov. 28, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology an...

2022-11-28 08:00 5442

AstraZeneca Thailand Wins Two ACES Awards 2022: "Industry Champions of the Year" and "Community Initiative"

BANGKOK, Nov. 25, 2022 /PRNewswire/ -- AstraZeneca (Thailand) Co., Ltd., was recently honoured with two accolades in the categories ofIndustry Champions of the Year and Community Initiative at the Asia Corporate Excellence & Sustainability Awards 2022(ACES Awards 2022).

2022-11-25 10:00 5016

AstraZeneca Certified Best Place to Work in Indonesia for 2022

JAKARTA, Indonesia, Nov. 24, 2022 /PRNewswire/ -- AstraZeneca Indonesia, a ffiliate of the multinational pharmaceutical and biopharmaceutical company,was recently recognized as the Best Place to Work in Indonesia for 2022. The company received outstanding scores across several aspects of their wo...

2022-11-24 21:35 5161

Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDA

--The Phase I clinical trial will consist of 3 cohorts in healthy subjects, including single- and multiple-dose escalation studies and food effect study. The objective of Phase I trial is to find a right dose to move into the pivotal Phase II/III in COVID-19 patients --In antiviral cellular assa...

2022-11-23 19:43 4795

PUBLICATION OF THE OFFERING CIRCULAR IN RELATION TO THE MERGER BETWEEN DSM and Firmenich and the LISTING OF DSM-Firmenich ON EURONEXT AMSTERDAM

THIS PRESS RELEASE IS NOT FOR GENERAL RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO, DIRECTLY OR INDIRECTLY,THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR REGULATIONS This is a joint press relea...

2022-11-22 15:06 2963

3Z: Zebrafish mutant model reveals novel drug candidates for ADHD

REYKJAVIK, Iceland, Nov. 22, 2022 /PRNewswire/ -- ADHD is a highly prevalent neurodevelopmental disorder. The first-line therapeutic for ADHD, methylphenidate, is beneficial for only a subset of patients and can cause side effects including weight loss, insomnia and hypertension. Therefore, the ...

2022-11-22 10:54 3150

Better treatments for breast cancer! Latest Clinical Data of Bispecific Antibodies will be presented at SABCS 2022 By Alphamab Oncology

SUZHOU, China, Nov. 22, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that results from three clinical studies of KN026 (anti-HER2 bispecific antibody) and KN046 (PD-L1/CTLA4 bispecific antibody) will be presented as Spotlight Poster Discussion or Poster Presentation at t...

2022-11-22 09:18 4700
1 ... 120121122123124125126 ... 185